quinoxalines has been researched along with Neoplasms in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.00) | 18.7374 |
| 1990's | 11 (11.00) | 18.2507 |
| 2000's | 14 (14.00) | 29.6817 |
| 2010's | 56 (56.00) | 24.3611 |
| 2020's | 12 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avadhani, A; De Porre, P; Dosne, AG; Faelens, R; Leirens, Q; Li, LY; O'Hagan, A; Ouellet, D; Perez Ruixo, JJ; Poggesi, I; Stuyckens, K; Valade, E | 1 |
| Ammar, YA; Farrag, AM; Fayed, EA; Gohar, NA | 1 |
| Feng, LS; Gao, C; Liu, FW; Wang, XP; Zhang, ZL | 1 |
| Chen, L; Chen, Y; Deng, D; Guo, Y; He, W; Liu, K; Peng, B; Si, W; Tang, M; Xiang, M; Xu, D; Xu, Q; Yang, T; Yang, Y; Yuan, X; Zhang, C; Zhang, S; Zou, Y | 1 |
| Gonzalez, M; Guo, Y; Li, LY; Ouellet, D | 1 |
| Castelli, R; Lodola, A; Marseglia, G; Mor, M | 1 |
| Dosne, AG; Li, LY; Ouellet, D; Perez-Ruixo, JJ; Stuyckens, K; Valade, E | 1 |
| de Almeida Carvalho, LM; de Oliveira Sapori Avelar, S; Gill, J; Haslam, A; Prasad, V | 1 |
| Fan, Q; Jiang, X; Li, S; Wang, R; Wu, W; Yin, C | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Babar, DA; Chopra, S; Kalari, S; Karale, UB; Kaul, G; Makane, VB; Misra, S; Rekha, EM; Rode, HB; Shukla, M; Sriram, D; Vamshi Krishna, E | 1 |
| Li, K; Li, Y; Lin, X; Ni, JS; Wang, L; Zha, M; Zhang, X; Zhang, Y | 1 |
| Babiker, HM; Chandana, SR; Mahadevan, D | 1 |
| Curti, C; Giuglio-Tonolo, AG; Terme, T; Vanelle, P | 1 |
| Gupta, S; Kaur, P; Kumar, R; Malhotra, SV; Pandrala, M; Salunke, DB; Singh, R; Tailor, D | 1 |
| Camisa, H; Dedieu, JF; Edelman, G; Ghuysen, AF; Lager, J; Liu, L; LoRusso, PM; Mehnert, JM; Sharma, J; Stein, M | 1 |
| Ding, D; Fang, Y; Hu, X; Kwok, RTK; Lam, JWY; Qi, J; Tang, BZ; Zhang, X | 1 |
| Ali, I; Choi, G; Go, A; Lee, J; Lee, K | 1 |
| Aoki, M; Doi, T; Iwasawa, R; Nishina, T; Noguchi, H; Takahashi, S | 1 |
| Hu, W; Li, X; Shi, L; Wu, J; Zhou, H | 1 |
| Bekhradnia, A; Ghanbarimasir, Z; Kardan, M; Morteza-Semnani, K; Rafiei, A; Razzaghi-Asl, N | 1 |
| Castell, C; Edelman, G; Jiang, J; Lager, J; Lindeman, NI; Rodon, J; Shapiro, GI; Sholl, LM; Van Allen, EM; Wagle, N | 1 |
| Biroccio, A; Ciriolo, MR; Del Bufalo, D; Di Leo, L; Iachettini, S; Leonetti, C; Lucidi, A; Mai, A; Rizzo, A; Rotili, D; Salvati, E; Steegborn, C; Trisciuoglio, D; Zizza, P | 1 |
| Ashton, TM; Herbert, KJ; Higgins, GS; Pirovano, G; Prevo, R | 1 |
| Campana, F; Damstrup, L; Gandhi, L; Grande, E; Heist, RS; Hidalgo, M; Hyman, DM; Mita, MM; Schram, AM | 1 |
| Mathias, F; Montana, M; Terme, T; Vanelle, P | 1 |
| Saad, EA; Waly, HM | 1 |
| Awad, M; Bahleda, R; Calvo, E; Cervantes, A; Chan, N; Gonzalez, M; Govindan, R; Hierro, C; Infante, J; Italiano, A; Mita, A; Moreno, V; Parekh, T; Poggesi, I; Santiago-Walker, A; Spira, A; Tabernero, J; Xie, H; Zhong, B | 1 |
| Amini, M; Azizian, H; Hamedifar, H; Mahdavi, M; Mahdi Didehvar, M; Mohammed, EHM; Ostad, S; Rezaei, Z | 1 |
| Adekoya, JA; Ajanaku, CO; Ajani, OO; Nlebemuo, MT; Ogunniran, KO; Siyanbola, TO | 1 |
| Dosne, AG; Kleiman, R; Li, LY; Ouellet, D; Perez-Ruixo, JJ; Valade, E; Xie, H | 1 |
| Dou, B; Fan, J; Peng, X; Wang, J; Zhang, H; Zhang, S | 1 |
| Fu, YH; Gao, JQ; Han, M; He, QJ; Hu, YZ; Li, LM; Meng, QH; Sheng, XX; Tang, XJ; Yang, B; Ying, XY; Zeng, S | 1 |
| Bartholomew, P; Elwell, M; Radi, Z; Vogel, WM | 1 |
| Gamazon, ER; Innocenti, F; Kim, TW; Liu, W; Mirkov, S; Mulkey, F; Myers, JL; Owzar, K; Ramírez, J; Ratain, MJ; Stock, W; Undevia, S; Watson, D | 1 |
| Cohen, RB; Engelman, JA; Felip, E; Jänne, PA; Laird, AD; Macé, S; Martinez, P; Rockich, K; Ruiz-Soto, R; Shapiro, GI; Xu, J | 1 |
| Briguglio, I; Carta, A; Corona, P; Costi, MP; Ferrari, S; Luciani, R; Paglietti, G; Piras, S | 1 |
| Baselga, J; Egile, C; Laird, AD; Lorusso, PM; Markman, B; Miles, D; Papadopoulos, KP; Patnaik, A; Ruiz-Soto, R; Shi, W; Tabernero, J; Tolcher, AW | 1 |
| Abulafia, W; Bentzien, F; Buhr, CA; Chen, J; Chu, F; Dale, S; Du, X; Foster, P; Hsu, PP; Jaeger, CT; Laird, AD; Lam, ST; Lamb, P; Lee, M; Matthews, DJ; Plonowski, A; Qian, F; Shen, P; Won, KA; Wu, J; Yakes, FM; Yamaguchi, K; Young, J; Yu, P; Zhang, W | 1 |
| Chellaian, JD; Johnson, J | 1 |
| Babu, PV; Kulkarni, P; Medishetti, R; Pal, M; Sunke, R; Yellanki, S | 1 |
| Aldrich-Wright, JR; Ang, DL; Clegg, JK; Danchaiwijit, S; Kepert, CJ; Li, F; Pages, BJ; Spare, LK; Wormell, P | 1 |
| Bříza, T; Dolenský, B; Džubák, P; Hajdúch, M; Kejík, Z; Král, V; Králová, J; Martásek, P; Mikula, I; Poučková, P; Rimpelová, S; Ruml, T | 1 |
| Ahn, CH; Kim, DJ; Kost, GC; Lee, YB; Li, L; Liu, CY; Liu, ZR; Yang, MY; Zhang, Y | 1 |
| Kim, DK; Li, J; Liu, Y; Shim, YK; Wang, JJ; Yin, JG; Yoon, I; Zhang, X | 1 |
| Liu, H; Wei, Q; Zhang, D; Zhang, Z; Zhou, H; Zhou, Q | 1 |
| Lewin, J; Siu, LL | 1 |
| Adamo, B; Bahleda, R; Calvo, E; Chatterjee-Kishore, M; Dienstmann, R; Gazzah, A; Infante, JR; Italiano, A; Luo, FR; Mita, A; Moreno, V; Peddareddigari, V; Platero, SJ; Rodon, J; Smit, JW; Soria, JC; Stuyckens, K; Tabernero, J; Zhong, B | 1 |
| Caflisch, A; Dong, J; Kolb, P; Lafleur, K; Liebl, J; Nevado, C; Unzue, A; Zahler, S; Zhao, H; Zhou, T | 1 |
| Aiello, F; Garofalo, A; Grande, F; Neamati, N | 1 |
| Araki, N; Hayashida, Y; Ikeda, Y; Kakehi, Y; Kato, T; Kawai, K; Sawada, K | 1 |
| Cao, JY; Dixon, SJ | 1 |
| Bechter, OE; Costermans, J; Dedieu, JF; Dumez, H; Francesconi, E; Ghuysen, AF; Hsu, K; Liu, L; Punie, K; Schöffski, P; Sharma, J | 1 |
| Balogh, B; Barraja, P; Carbone, A; Cascioferro, S; Diana, P; Montalbano, A; Parrino, B; Spanò, V | 1 |
| Castell, C; Jiang, J; Lager, J; Liu, L; Mutch, D; Traynor, AM; Wheler, J | 1 |
| Desai, AA; House, L; Innocenti, F; Karrison, T; Kindler, HL; Ramirez, J; Ratain, MJ; Singh, DA; Skoog, LA; Undevia, SD | 1 |
| Hu, C; Lee, H; Solomon, VR; Ulibarri, G | 1 |
| Davis, DP; De Mazière, A; Degtyarev, M; Friedman, LS; Gray, DC; Hoeflich, KP; Klumperman, J; Lee, BB; Lin, J; Lin, K; Murray, LJ; Orr, C; Prior, WW; Stern, HM; Tien, JY; van Dijk, S; Wu, H | 1 |
| Aiello, F; Cao, X; Garofalo, A; Grande, F; Neamati, N; Oshima, T; Plasencia, C; Sanchez, T; Yamada, R | 1 |
| Balzarini, J; Baráth, Z; Das, U; De Clercq, E; Dimmock, JR; Kawase, M; Molnár, J; Ocsovszki, I; Panda, AK; Pati, HN; Sakagami, H; Zhou, L | 1 |
| Eguchi, T; Hirai, H; Itadani, H; Kawanishi, N; Kotani, H; Shimomura, T | 1 |
| Chen, J; Huang, M; Madiyalakan, R; Meng, Y; Swanson, E; Woo, T; Xing, JZ; Yang, X; Zou, C | 1 |
| Abdelsamie, AS; Atta, MH; El Diwani, HI; Elhefnawi, MM; Galal, SA; Lida, A; Ramadan, RA; Suzuki, N; Tokuda, H | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Grief, SN | 1 |
| Beavers, CM; El-Khatib, M; Farber, KM; Fettinger, JC; Haddadin, MJ; Kurth, MJ; Olmstead, MM; Shoker, TA | 1 |
| Ahn, CH; Gong, YD; Kang, NS; Kim, DJ; Kong, JY; Lee, YB | 1 |
| Hu, Y; Liu, X; Shangguan, S; Sheng, R; Xia, Q | 1 |
| Dong, X; Guan, X; Hu, Y; Huang, W; Liu, X; Su, Y; Wu, P; Zhang, J | 1 |
| Ai, J; Chen, T; Geng, M; Ji, Y; Liu, Q; Peng, X; Wang, Y; Wu, K; Xu, Y; Yao, Q; Zhang, A; Zhao, A | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Reynolds, CP; Smith, MA | 1 |
| Hebar, A; Rütgen, BC; Selzer, E | 1 |
| Dautzenberg, B | 1 |
| Mai, L; Wei, Q; Yao, A; Zhang, D; Zhang, Z; Zhou, Q | 1 |
| Friesen, MD; Qian, Z; Rothman, N; Sinha, R; Strickland, PT | 1 |
| Sinha, R | 1 |
| Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL | 1 |
| Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y | 1 |
| Busonera, B; Carta, A; Collu, G; La Colla, P; Loddo, R; Loriga, M; Paglietti, G; Piras, S | 1 |
| Darga, TE; Efimova, EV; Garofalo, M; Katdare, M; Khodarev, NN; Kufe, DW; Labay, E; Nakamura, S; Posner, MC; Weichselbaum, RR | 1 |
| Lathan, B; Von Hoff, DD | 1 |
| Bogden, AE; Cobb, WR; Griffin, TW; Kelton, DE; LePage, DJ; Reich, SD | 1 |
| Conley, BA; Egorin, MJ; Melink, TJ; O'Hara, S; Pardoe, E; Parnes, H; Van Echo, DA; Wu, S | 1 |
| Francis, PA; Kris, MG; Miller, VA; Orazem, JP; Rigas, JR; Roistacher, N; Tong, WP; Warrell, RP; Young, CW | 1 |
| Adamson, RH; Sugimura, T; Thorgeirsson, UP | 1 |
| Nagao, M; Sugimura, T; Totsuka, Y; Toyota, M; Ushijima, T; Wakabayashi, K | 1 |
| Bhadresa, S; Boobis, AR; Bratt, C; Crosbie, SJ; Davies, DS; Edwards, RJ; Gooderham, NJ; Lynch, AM; Murray, BP; Murray, S; Rich, KJ; Yadollahi-Farsani, M; Zhao, K | 1 |
| Felton, JS; Frantz, C; McManus, M; Turteltaub, KW; Vogel, JS | 1 |
| Sugimura, T | 1 |
| Arbuck, SG; Christian, MC; Collins, J; Freidlin, B; Rubinstein, L; Simon, R | 1 |
| Henderson, BE; Kidd, LC; Ross, RK; Skipper, PL; Stillwell, WG; Tannenbaum, SR; Wishnok, JS; Yu, MC | 1 |
| Corona, P; Loriga, M; Paglietti, G; Vitale, G | 1 |
| Ding, Z; Lawrence, TS; Li, J; LoRusso, PM; Parchment, RE; Sun, Y; Wu, GS; Zhou, JY | 1 |
| Kris, MG; Orazem, JP; Rigas, JR; Tong, WP; Warrell, RP; Young, CW | 1 |
| Clark, GM; Coltman, CA; Hersh, M; Kuhn, JG; Melink, T; Von Hoff, DD; Weiss, GR | 1 |
| Liu, ZC; Nagao, M; Sugimura, T; Wakabayashi, K; Zhang, XM | 1 |
| Furihata, C; Matsushima, T | 1 |
| Ahlgren, JD; Andrews, WG; Byrne, PJ; Harvey, JH; McFadden, M; Woolley, PV | 1 |
| Brewer, WR; Briscoe, JR; Vivian, DL | 1 |
22 review(s) available for quinoxalines and Neoplasms
| Article | Year |
|---|---|
Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022).
Topics: Antineoplastic Agents; Drug Discovery; Humans; Neoplasms; Quinoxalines; Structure-Activity Relationship | 2022 |
Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
Topics: Animals; Antineoplastic Agents; Drug Development; Humans; Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Fibroblast Growth Factors; Humans; Molecular Targeted Therapy; Morpholines; Neoplasms; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, Fibroblast Growth Factor | 2020 |
A Survey of Synthetic Routes and Antitumor Activities for Benzo[
Topics: Anthraquinones; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasms; Quinoxalines; Structure-Activity Relationship; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2020 |
Quinoxalinone as a Privileged Platform in Drug Development.
Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Drug Design; Enzyme Inhibitors; Fungi; Humans; Molecular Structure; Neoplasms; Quinoxalines | 2018 |
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Drug Discovery; Humans; Indolizines; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Quinolones; Quinoxalines; Thiophenes; Treatment Outcome | 2018 |
Antitumoral activity of quinoxaline derivatives: A systematic review.
Topics: Antineoplastic Agents; Humans; Neoplasms; Quinoxalines | 2019 |
Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Development; Drug Discovery; Humans; Neoplasms; Quinoxalines | 2019 |
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
Topics: Animals; Benzazepines; Carcinogenicity Tests; Disease Models, Animal; Humans; Hydromorphone; Lipoma; Mutagenicity Tests; Neoplasms; Phentolamine; Piperidines; Pyrimidines; Pyrroles; Quinoxalines; Rats; Risk Assessment; Varenicline | 2013 |
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.
Topics: Animals; Computer Simulation; Drug Design; Humans; Isoquinolines; Neoplasms; Protein Kinase Inhibitors; Quinoxalines; Receptor, EphB2; Structure-Activity Relationship; Xanthine | 2016 |
Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Discovery; Humans; Hydrazines; Molecular Structure; Neoplasms; Quinoxalines | 2016 |
Mechanisms of ferroptosis.
Topics: Cell Death; Cell Membrane; Cyclohexylamines; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Iron; Neoplasms; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Quinoxalines; Reactive Oxygen Species; Spiro Compounds | 2016 |
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Humans; Neoplasms; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; Varenicline | 2011 |
Metabolites of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) in human urine after consumption of charbroiled or fried beef.
Topics: Animals; Carcinogens; Chromatography, High Pressure Liquid; Cooking; Dietary Proteins; Eating; Glucuronides; Heterocyclic Compounds; Humans; Imidazoles; Meat Products; Mutagens; Neoplasms; Quinoxalines | 2002 |
An epidemiologic approach to studying heterocyclic amines.
Topics: Amines; Animals; Carcinogens; Cooking; Diet; Dietary Proteins; Epidemiologic Studies; Heterocyclic Compounds; Humans; Imidazoles; Meat Products; Neoplasms; Quinoxalines; Risk Factors; Surveys and Questionnaires | 2002 |
MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline).
Topics: Animals; Carcinogens; Cooking; Fishes; Food; Food Analysis; Humans; Meat; Neoplasms; Quinoxalines | 1993 |
Extrapolation of heterocyclic amine carcinogenesis data from rodents and nonhuman primates to humans.
Topics: Amines; Animals; Biotransformation; Carcinogens; Diet; Food Handling; Heterocyclic Compounds; Humans; Imidazoles; Meat; Mice; Mutagens; Neoplasms; Primates; Quinoxalines; Rats; Risk Assessment; Species Specificity; Structure-Activity Relationship | 1996 |
Human exposure to carcinogenic heterocyclic amines and their mutational fingerprints in experimental animals.
Topics: Amines; Animals; Carcinogens, Environmental; DNA Adducts; Environmental Exposure; Food Contamination; Heterocyclic Compounds; Humans; Imidazoles; Mutagens; Mutation; Neoplasms; Quinoxalines | 1996 |
Heterocyclic amines: evaluation of their role in diet associated human cancer.
Topics: Animals; Biological Availability; Carcinogens; Diet; Humans; Imidazoles; Meat; Mutagens; Neoplasms; Quinoxalines | 1996 |
Assessment of the DNA adduction and pharmacokinetics of PhIP and MeIOx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling.
Topics: Animals; Carcinogens; DNA Adducts; Humans; Imidazoles; Mass Spectrometry; Mutagens; Neoplasms; Phosphorus Radioisotopes; Quinoxalines; Radioisotope Dilution Technique; Rodentia | 1995 |
Mutagens and carcinogens in foods.
Topics: Amines; Amino Acids; Animals; Carbohydrate Metabolism; Carcinogens; Chemical Phenomena; Chemistry; Creatinine; Diacetyl; Dietary Proteins; Food; Food Analysis; Glyoxal; Heterocyclic Compounds; Hot Temperature; Humans; Microsomes, Liver; Mutagenicity Tests; Mutagens; Neoplasms; Polycyclic Compounds; Pyruvaldehyde; Quinoxalines | 1986 |
16 trial(s) available for quinoxalines and Neoplasms
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Tablets | 2018 |
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Topics: Aged; Area Under Curve; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Treatment Outcome | 2018 |
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Safety; Sulfonamides; Tablets; Treatment Outcome | 2018 |
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases | 2018 |
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Retreatment; Treatment Outcome; Young Adult | 2019 |
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Electrocardiography; Female; Follow-Up Studies; Heart; Heart Rate; Humans; Male; Middle Aged; Neoplasms; Patient Safety; Prognosis; Pyrazoles; Quinoxalines; Tissue Distribution; Young Adult | 2019 |
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinoxalines; Safety; Sulfonamides; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases | 2014 |
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2014 |
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor | 2015 |
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capsules; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Tablets | 2016 |
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2017 |
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Quinoxalines; Treatment Outcome | 2008 |
Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.
Topics: Adult; Aged; Antineoplastic Agents; Body Weight; Bone Marrow; Female; Humans; Hypoglycemia; Male; Middle Aged; Neoplasms; Quinoxalines; Sulfanilamides | 1995 |
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypoglycemia; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Quinoxalines; Sulfanilamides | 1995 |
Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Administration Schedule; Female; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Neoplasms; Quinoxalines; Sulfanilamides | 1992 |
63 other study(ies) available for quinoxalines and Neoplasms
| Article | Year |
|---|---|
Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.
Topics: Female; Humans; Neoplasms; Phosphates; Pyrazoles; Quinoxalines | 2022 |
Upregulation of BAX and caspase-3, as well as downregulation of Bcl-2 during treatment with indeno[1,2-b]quinoxalin derivatives, mediated apoptosis in human cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Humans; Neoplasms; Quinoxalines; Structure-Activity Relationship; Up-Regulation | 2022 |
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening.
Topics: Ataxia Telangiectasia Mutated Proteins; Early Detection of Cancer; Goals; Humans; Irinotecan; Neoplasms; Quinoxalines | 2023 |
Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis.
Topics: Adolescent; Adult; Area Under Curve; Blood Proteins; Clinical Trials, Phase I as Topic; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Orosomucoid; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Serum Albumin, Human; Young Adult | 2020 |
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Topics: Administration, Oral; Adult; Aged; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines | 2020 |
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
Topics: Antineoplastic Agents; Genetic Variation; Humans; Neoplasms; Off-Label Use; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms | 2019 |
Second Near-Infrared Aggregation-Induced Emission Fluorophores with Phenothiazine Derivatives as the Donor and 6,7-Diphenyl-[1,2,5]Thiadiazolo[3,4-g]Quinoxaline as the Acceptor for In Vivo Imaging.
Topics: Animals; Cell Line, Tumor; Fluorescent Dyes; Humans; Male; Mice, Inbred ICR; Mice, Nude; Micelles; Neoplasms; Optical Imaging; Phenothiazines; Poloxamer; Quinoxalines; Thiadiazoles | 2020 |
Synthesis of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines, pyrrolo[1,2-a]quinoxalin]-2-ones and their antituberculosis and anticancer activity.
Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Design; HeLa Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Melanoma, Experimental; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Neoplasms; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2020 |
An Ester-Substituted Semiconducting Polymer with Efficient Nonradiative Decay Enhances NIR-II Photoacoustic Performance for Monitoring of Tumor Growth.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Density Functional Theory; Drug Screening Assays, Antitumor; Esters; Humans; Infrared Rays; Mice; Molecular Structure; Nanoparticles; Neoplasms; Photoacoustic Techniques; Photothermal Therapy; Polymers; Quinoxalines; Semiconductors | 2020 |
Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation.
Topics: Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasms; Quinoxalines; Structure-Activity Relationship | 2021 |
Highly Stable Organic Small Molecular Nanoparticles as an Advanced and Biocompatible Phototheranostic Agent of Tumor in Living Mice.
Topics: Amines; Animals; Female; Hyperthermia, Induced; Infrared Rays; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Photoacoustic Techniques; Phototherapy; Quinoxalines; Terphenyl Compounds; Theranostic Nanomedicine; Thiadiazoles | 2017 |
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Evaluation, Preclinical; Half-Life; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Neoplasms; Nuclear Proteins; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Quinoxalines; Rats; Structure-Activity Relationship; Triazoles | 2017 |
Design, synthesis, biological assessment and molecular docking studies of new 2-aminoimidazole-quinoxaline hybrids as potential anticancer agents.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Humans; Imidazoles; Molecular Docking Simulation; Molecular Structure; Neoplasms; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells.
Topics: Acetylation; AMP-Activated Protein Kinases; Apoptosis; Autophagosomes; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle; Cell Proliferation; Enzyme Activation; HCT116 Cells; HeLa Cells; Histones; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Pyrroles; Quinoxalines; Reactive Oxygen Species; Signal Transduction; Sirtuins | 2018 |
Encapsulation of a new quinoxaline derivative in PLGA alters the pattern of its anticancer potency and induces apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Damage; Drug Carriers; Drug Delivery Systems; Drug Liberation; Flow Cytometry; Humans; Inhibitory Concentration 50; Nanoparticles; Neoplasms; Oxidative Stress; Polylactic Acid-Polyglycolic Acid Copolymer; Quinoxalines | 2019 |
Anticancer properties of N-alkyl-2, 4-diphenylimidazo [1, 2-a] quinoxalin-1-amine derivatives; kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
An off-on COX-2-specific fluorescent probe: targeting the Golgi apparatus of cancer cells.
Topics: Acenaphthenes; Cell Line, Tumor; Cyclooxygenase 2; Fluorescent Dyes; Golgi Apparatus; Humans; Indomethacin; Models, Molecular; Neoplasms; Optical Imaging; Quinoxalines | 2013 |
Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Drug Compounding; Drug Stability; Hep G2 Cells; Humans; Male; Mice; Mice, Nude; Nanoparticles; Neoplasms; Poloxamer; Pressure; Quinoxalines; Solubility; Surface-Active Agents; Suspensions; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
Topics: Aldehyde Oxidase; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Cohort Studies; Genetic Variation; Genotype; Humans; Liver; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Quinoxalines | 2014 |
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Folic Acid; Folic Acid Antagonists; Halogenation; Humans; Methylation; Molecular Docking Simulation; Neoplasms; Quinoxalines; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2014 |
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Humans; Inhibitory Concentration 50; Mice; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Spectral characterization, electrochemical and anticancer studies on some metal(II) complexes containing tridentate quinoxaline Schiff base.
Topics: Anti-Infective Agents; Antineoplastic Agents; Aspergillus niger; Bacteria; Candida albicans; DNA; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Metals; Microbial Sensitivity Tests; Neoplasms; Quinoxalines; Schiff Bases; Spectrum Analysis | 2014 |
Ligand-free MCR for linking quinoxaline framework with a benzimidazole nucleus: a new strategy for the identification of novel hybrid molecules as potential inducers of apoptosis.
Topics: Animals; Apoptosis; Benzimidazoles; Catalysis; Copper; Dose-Response Relationship, Drug; Drug Design; Ethylamines; Humans; Iodides; Ligands; Microscopy, Fluorescence; Neoplasms; Quinoxalines; Zebrafish | 2014 |
Synthesis and analysis of the anticancer activity of platinum(II) complexes incorporating dipyridoquinoxaline variants.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Crystallography, X-Ray; Cyclohexylamines; DNA; Humans; Intercalating Agents; Models, Molecular; Neoplasms; Organoplatinum Compounds; Quinoxalines | 2014 |
Striking antitumor activity of a methinium system with incorporated quinoxaline unit obtained by spontaneous cyclization.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclization; Hexamethonium; Mice; Neoplasms; Quinoxalines | 2015 |
A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-Fluoro-2-Methoxyquinoxalin-3-yl)Aminocarbonyl] Piperazine (RX-5902), Interferes With β-Catenin Function Through Y593 Phospho-p68 RNA Helicase.
Topics: Antineoplastic Agents; beta Catenin; Binding Sites; Cell Line, Tumor; DEAD-box RNA Helicases; Humans; Neoplasms; Phosphorylation; Piperazines; Protein Binding; Quinoxalines; Signal Transduction | 2015 |
Synthesis, optical properties and preliminary in vitro photodynamic effect of pyridyl and quinoxalyl substituted chlorins.
Topics: Chlorophyll; Chlorophyll A; HeLa Cells; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Pyridines; Quinoxalines | 2015 |
Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytosol; Disease Models, Animal; Gene Expression; Gene Silencing; Humans; Liver Neoplasms; Male; Metabolic Networks and Pathways; Mice; Neoplasms; Quinoxalines; Thymidine; Thymidine Kinase; Thymidine Phosphorylase; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?
Topics: Antineoplastic Agents; Humans; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor | 2015 |
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Humans; Light; Macrophages; Mice; Molecular Imaging; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Photosensitizing Agents; Quinoxalines; Reactive Oxygen Species; Sulfonamides | 2016 |
Investigation of Isoindolo[2,1-a]quinoxaline-6-imines as Topoisomerase I Inhibitors with Molecular Modeling Methods.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; DNA Topoisomerases, Type I; Humans; Imines; Isoindoles; Molecular Docking Simulation; Neoplasms; Quinoxalines; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2017 |
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Chloroquine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Stereoisomerism; Structure-Activity Relationship | 2008 |
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 7; Benzylamines; Cell Cycle; Cell Line, Tumor; Chloroquine; Drug Interactions; Female; Furans; Humans; Lysosomes; Macrolides; Mice; Mice, Nude; Mitochondria; Mutation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proton-Translocating ATPases; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinoxalines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2008 |
Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Discovery; Female; Flow Cytometry; HT29 Cells; Humans; Hydrazines; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Structure; Neoplasms; Quinoxalines; Xenograft Model Antitumor Assays | 2009 |
2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Inhibitory Concentration 50; Male; Mice; Molecular Structure; Neoplasms; Oxides; Quantitative Structure-Activity Relationship; Quinoxalines | 2009 |
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p18; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; Humans; Macrocyclic Compounds; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Spodoptera; Transfection | 2009 |
Water-soluble and biocompatible sono/photosensitizer nanoparticles for enhanced cancer therapy.
Topics: Animals; Cell Line, Tumor; Cell Survival; Humans; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Perylene; Photochemotherapy; Photosensitizing Agents; Quinoxalines; Solubility; Water | 2010 |
Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
Topics: Animals; Antigens, Viral; Antineoplastic Agents; Binding Sites; Drug Design; Female; Hydrogen Bonding; Mice; Models, Molecular; Neoplasms; Protein Conformation; Proto-Oncogene Proteins c-kit; Quinoxalines; Reproducibility of Results | 2011 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Quinoxalino[2,3-c]cinnolines and their 5-N-oxide: alkoxylation of methyl-substituted quinoxalino[2,3-c]cinnolines to acetals and orthoesters.
Topics: Acetals; Alcohols; Antineoplastic Agents; Benzoxazoles; Chemistry, Pharmaceutical; Cyanides; Cyclization; Esters; Heterocyclic Compounds, 2-Ring; Humans; Magnetic Resonance Spectroscopy; Neoplasms; Oxides; Quinoxalines; Tirapazamine; Triazines | 2011 |
Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Male; Neoplasms; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2012 |
Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Nitriles; Quinoxalines | 2012 |
Identification of novel piperazinylquinoxaline derivatives as potent phosphoinositide 3-kinase (PI3K) inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Flow Cytometry; HL-60 Cells; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mass Spectrometry; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Tetrazolium Salts; Thiazoles | 2012 |
Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
Topics: Antineoplastic Agents; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinoxalines; Structure-Activity Relationship | 2012 |
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Shape; Cell Size; DNA Damage; DNA Replication; Drug Screening Assays, Antitumor; Humans; Hydrazines; Inhibitory Concentration 50; Neoplasms; Phosphorylation; Quinoxalines; S Phase Cell Cycle Checkpoints; Tumor Suppressor Protein p53 | 2012 |
[Methods and results of smoking cessation in cancer smoker's].
Topics: Benzazepines; Bupropion; Humans; Neoplasms; Nicotinic Agonists; Quinoxalines; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Industry; Tobacco Smoke Pollution; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2012 |
Design, synthesis, and in vitro and in vivo biological studies of a 3'-deoxythymidine conjugate that potentially kills cancer cells selectively.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Proliferation; Drug Design; Fluorescence; Humans; Liver; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mitochondria; Molecular Structure; Neoplasms; Quinoxalines; Superoxides; Thymidine; Tumor Cells, Cultured | 2012 |
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines | 2002 |
The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclic N-Oxides; Female; Fluorescent Antibody Technique; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasm Transplantation; Neoplasms; Quinoxalines; Tirapazamine; Triazines | 2005 |
Synthesis of variously substituted 3-phenoxymethyl quinoxalin-2-ones and quinoxalines capable to potentiate in vitro the antiproliferative activity of anticancer drugs in multi-drug resistant cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Etoposide; Humans; KB Cells; Neoplasms; Quinoxalines; Tumor Cells, Cultured; Vincristine | 2006 |
Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cellular Senescence; Humans; Imidazoles; Necrosis; Neoplasms; NF-kappa B; Quinoxalines; Tumor Necrosis Factor-alpha | 2007 |
Cytotoxic activity of echinomycin in a human tumor cloning system.
Topics: Cell Survival; Cells, Cultured; Echinomycin; Female; Humans; Male; Neoplasms; Quinoxalines; Tumor Stem Cell Assay | 1984 |
Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assay.
Topics: Animals; Cyclophosphamide; Drug Evaluation; Echinomycin; Female; Formamides; Humans; Mice; Neoplasms; Quinoxalines; Transplantation, Heterologous | 1983 |
An overview of cancer prevention.
Topics: beta Carotene; Carcinogens; Cell Transformation, Neoplastic; Chemoprevention; Environmental Exposure; Humans; Imidazoles; Mutagens; Neoplasms; Neoplasms, Unknown Primary; Precancerous Conditions; Primary Prevention; Quinoxalines; Risk Factors | 1996 |
Accelerated titration designs for phase I clinical trials in oncology.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Humans; Models, Statistical; Neoplasms; Quinoxalines; Research Design; Sulfanilamides | 1997 |
Urinary excretion of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in White, African-American, and Asian-American men in Los Angeles County.
Topics: Adult; Asian; Black People; Humans; Imidazoles; Los Angeles; Male; Meat; Neoplasms; Quinoxalines; Surveys and Questionnaires; White People | 1999 |
Quinoxaline chemistry. Part 13: 3-Carboxy-2-benzylamino-substituted quinoxalines and N-[4-[(3-carboxyquinoxalin-2-yl) aminomethyl]benzoyl]-L-glutamates: synthesis and evaluation of in vitro anticancer activity.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Evaluation; Glutamates; Humans; Neoplasms; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured | 2000 |
The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Mutation; Neoplasms; Quinoxalines; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
Topics: Adult; Aged; Drug Evaluation; Echinomycin; Female; Humans; Infusions, Intravenous; Liver Function Tests; Male; Middle Aged; Nausea; Neoplasms; Platelet Count; Quinoxalines; Thrombocytopenia; Vomiting | 1989 |
Mutagenic and carcinogenic heterocyclic amines in Chinese cooked foods.
Topics: China; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Cooking; Diet; Food Analysis; Heterocyclic Compounds; Imidazoles; Mutagenicity Tests; Mutagens; Mutation; Neoplasms; Quinolines; Quinoxalines | 1988 |
Phase I study of echinomycin administered on an intermittent bolus schedule.
Topics: Adult; Aged; Alanine Transaminase; Anaphylaxis; Aspartate Aminotransferases; Droperidol; Drug Administration Schedule; Drug Evaluation; Echinomycin; Female; Hematologic Diseases; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinoxalines | 1985 |
Cancer-preventable?
Topics: Animals; Antineoplastic Agents; Female; Methylcellulose; Mice; Mice, Inbred Strains; Naphthalenes; Neoplasms; Plant Extracts; Quinoxalines | 1972 |